Treatment of type 2 diabetes by free fatty acid receptor agonists

Frontiers in Endocrinology

Volumn 5, Issue AUG, 2014, Pages

  Watterson, Kenneth R ^a   Hudson, Brian D ^a   Ulven, Trond ^b   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Diabetes; FFA receptor; Incretin; Inflammation; Insulin

Indexed keywords

AMG 837; DS 1558; FASIGLIFAM; FATTY ACID; HEMOGLOBIN A1C; INCRETIN; LY 2881835; UNCLASSIFIED DRUG;

ADIPOGENESIS; APOPTOSIS; DESENSITIZATION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INSULIN RELEASE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL ASSESSMENT; OBESITY; REVIEW;

EID: 84987837271     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00137     Document Type: Review

References (95)

1. Alberti KG, Zimmet PZ. Diabetes: a look to the future. Lancet Diabetes Endocrinol (2014) 2:e1-2. doi: 10.1016/S2213-8587(13)70187-6
2. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med (2010) 363:2339-50. doi:10.1056/NEJMra0906948
3. Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine (2013) 44:47-58. doi:10.1007/s12020-013-9884-3
4. Offermanns S. Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors. Annu Rev Pharmacol Toxicol (2014) 54:407-34. doi:10.1146/annurev-pharmtox-011613-135945
5. Ferdaoussi M, Bergeron V, Zarrouki B, Kolic J, Cantley J, Fielitz J, et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia (2012) 55:2682-92. doi:10.1007/s00125-012-2650-x
6. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, Luo J, et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes (2007) 56:1087-94. doi:10.2337/db06-1532
7. Houze JB, Zhu L, Sun Y, Akerman M, Qiu W, Zhang AJ, et al. Amg 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett (2012) 22:1267-70. doi:10.1016/j.bmcl.2011.10.118
8. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, Chen M, et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One (2012) 7:e46300. doi:10.1371/journal.pone.0046300
9. Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, Carrero RJ, et al. The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology (2011) 140:903-12. doi:10.1053/j.gastro.2010.10.012
10. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes (2008) 57:2280-7. doi:10.2337/db08-0307
11. Nakamoto K, Nishinaka T, Sato N, Mankura M, Koyama Y, Kasuya F, et al. Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain. PLoS One (2013) 8:e81563. doi:10.1371/journal.pone.0081563
12. Ma D, Tao B, Warashina S, Kotani S, Lu L, Kaplamadzhiev DB, et al. Expression of free fatty acid receptor GPR40 in the central nervous system of adult monkeys. Neurosci Res (2007) 58:394-401. doi:10.1016/j.neures.2007.05.001
13. Flodgren E, Olde B, Meidute-Abaraviciene S, Winzell MS, Ahren B, Salehi A. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun (2007) 354:240-5. doi:10.1016/j.bbrc.2006.12.193
14. Wang L, Zhao Y, Gui B, Fu R, Ma F, Yu J, et al. Acute stimulation of glucagon secretion by linoleic acid results from GPR40 activation and [Ca2+]i increase in pancreatic islet alpha-cells. J Endocrinol (2011) 210:173-9. doi:10.1530/JOE-11-0132
15. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature (2003) 422:173-6. doi:10.1038/nature01478
16. Lan H, Hoos LM, Liu L, Tetzloff G, Hu W, Abbondanzo SJ, et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes (2008) 57:2999-3006. doi:10.2337/db08-0596
17. Hirasawa A, Itsubo C, Sadakane K, Hara T, Shinagawa S, Koga H, et al. Production and characterization of a monoclonal antibody against GPR40 (FFAR1; free fatty acid receptor 1). Biochem Biophys Res Commun (2008) 365:22-8. doi:10.1016/j.bbrc.2007.10.142
18. Cartoni C, Yasumatsu K, Ohkuri T, Shigemura N, Yoshida R, Godinot N, et al. Taste preference for fatty acids is mediated by GPR40 and GPR120. J Neurosci (2010) 30:8376-82. doi:10.1523/JNEUROSCI.0496-10.2010
19. Gilbertson TA, Khan NA. Cell signaling mechanisms of oro-gustatory detection of dietary fat: advances and challenges. Prog Lipid Res (2014) 53:82-92. doi:10.1016/j.plipres.2013.11.001
20. Kebede M, Ferdaoussi M, Mancini A, Alquier T, Kulkarni RN, Walker MD, et al. Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol-3-kinase-dependent O-GlcNAcylation of pancreas-duodenum homeobox-1. Proc Natl Acad Sci U S A (2012) 109:2376-81. doi:10.1073/pnas.1114350109
21. Nagasumi K, Esaki R, Iwachidow K, Yasuhara Y, Ogi K, Tanaka H, et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes (2009) 58:1067-76. doi:10.2337/db08-1233
22. Briscoe CP, Peat AJ, Mckeown SC, Corbett DF, Goetz AS, Littleton TR, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol (2006) 148:619-28. doi:10.1038/sj.bjp.0706770
23. Del Guerra S, Bugliani M, D'Aleo V, del Prato S, Boggi U, Mosca F, et al. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis (2010) 20:22-5. doi:10.1016/j.numecd.2009.02.008
24. Fontes G, Zarrouki B, Hagman DK, Latour MG, Semache M, Roskens V, et al. Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass. Diabetologia (2010) 53:2369-79. doi:10.1007/s00125-010-1850-5
25. Walker CG, Goff L, Bluck LJ, Griffin BA, Jebb SA, Lovegrove JA, et al. Variation in the FFAR1 gene modifies Bmi, body composition and beta-cell function in overweight subjects: an exploratory analysis. PLoS One (2011) 6:e19146. doi:10.1371/journal.pone.0019146
26. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The Ffa receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab (2005) 1:245-58. doi:10.1016/j.cmet.2005.03.007
27. Zhang Y, Xu M, Zhang S, Yan L, Yang C, Lu W, et al. The role of G protein-coupled receptor 40 in lipoapoptosis in mouse beta-cell line Nit-1. J Mol Endocrinol (2007) 38:651-61. doi:10.1677/JME-06-0048
28. Wu P, Yang L, Shen X. The relationship between GPR40 and lipotoxicity of the pancreatic beta-cells as well as the effect of pioglitazone. Biochem Biophys Res Commun (2010) 403:36-9. doi:10.1016/j.bbrc.2010.10.105
29. Wagner R, Kaiser G, Gerst F, Christiansen E, Due-Hansen ME, Grundmann M, et al. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes (2013) 62:2106-11. doi:10.2337/db12-1249
30. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther (2012) 340:483-9. doi:10.1124/jpet.111.187708
31. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther (2011) 339:228-37. doi:10.1124/jpet.111.183772
32. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab (2012) 14:271-8. doi:10.1111/j.1463-1326.2011.01525.x
33. Mancini AD, Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab (2013) 24:398-407. doi:10.1016/j.tem.2013.03.003
34. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, et al. Tak-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (2012) 379:1403-11. doi:10.1016/S0140-6736(11)61879-5
35. Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol (2012) 52:1007-16. doi:10.1177/0091270011409230
36. Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, Kipnes M, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, Tak-875, in subjects with type 2 diabetes. Clin Pharmacol Ther (2012) 92:29-39. doi:10.1038/clpt.2012.43
37. Burant CF. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. Diabetes Care (2013) 36(Suppl 2):S175-9. doi:10.2337/dcS13-2037
38. Bailey CJ. Could FFAR1 assist insulin secretion in type 2 diabetes? Lancet (2012) 379:1370-1. doi:10.1016/S0140-6736(12)60165-2
39. Poitout V, Lin DC. Modulating GPR40: therapeutic promise and potential in diabetes. Drug Discov Today (2013) 18:1301-8. doi:10.1016/j.drudis.2013.09.003
40. Lin DC, Guo Q, Luo J, Zhang J, Nguyen K, Chen M, et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol (2012) 82:843-59. doi:10.1124/mol.112.079640
41. Brown SP, Dransfield PJ, Vimolratana M, Jiao X, Zhu L, Pattaropong V, et al. Discovery of AM-1638: a potent and orally bioavailable GPR40/FFA1 full agonist. Acs Med Chem Lett (2012) 3:726-30. doi:10.1021/ml300133f
42. Wang Y, Liu J, Dransfield PJ, Zhu L, Wang Z, Du X, et al. Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles. Acs Med Chem Lett (2013) 4:551-5. doi:10.1021/ml300427u
43. Defossa E, Wagner M. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg Med Chem Lett (2014) 24:2991-3000. doi:10.1016/j.bmcl.2014.05.019
44. Takano R, Yoshida M, Inoue M, Honda T, Nakashima R, Matsumoto K, et al. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists. Bioorg Med Chem Lett (2014) 24:2949-53. doi:10.1016/j.bmcl.2014.04.065
45. Tanaka H, Yoshida S, Minoura H, Negoro K, Shimaya A, Shimokawa T, et al. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. Life Sci (2014) 94:115-21. doi:10.1016/j.lfs.2013.11.010
46. Tanaka H, Yoshida S, Oshima H, Minoura H, Negoro K, Yamazaki T, et al. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. J Pharmacol Exp Ther (2013) 346:443-52. doi:10.1124/jpet.113.206466
47. Christiansen E, Due-Hansen ME, Urban C, Merten N, Pfleiderer M, Karlsen KK, et al. Structure-activity study of dihydrocinnamic acids and discovery of the potent FFA1 (GPR40) agonist Tug-469. Acs Med Chem Lett (2010) 1:345-9. doi:10.1021/ml100106c
48. Christiansen E, Due-Hansen ME, Urban C, Grundmann M, Schroder R, Hudson BD, et al. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves Adme properties. J Med Chem (2012) 55:6624-8. doi:10.1021/jm3002026
49. Christiansen E, Hansen SV, Urban C, Hudson BD, Wargent ET, Grundmann M, et al. Discovery of Tug-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. Acs Med Chem Lett (2013) 4:441-5. doi:10.1021/ml4000673
50. Christiansen E, Urban C, Merten N, Liebscher K, Karlsen KK, Hamacher A, et al. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type Ii diabetes. J Med Chem (2008) 51:7061-4. doi:10.1021/jm8010178
51. Urban C, Hamacher A, Partke HJ, Roden M, Schinner S, Christiansen E, et al. In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469. Naunyn Schmiedebergs Arch Pharmacol (2013) 386:1021-30. doi:10.1007/s00210-013-0899-3
52. Christiansen E, Urban C, Grundmann M, Due-Hansen ME, Hagesaether E, Schmidt J, et al. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro Adme properties. J Med Chem (2011) 54:6691-703. doi:10.1021/jm2005699
53. Christiansen E, Due-Hansen ME, Urban C, Grundmann M, Schmidt J, Hansen SV, et al. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. J Med Chem (2013) 56:982-92. doi:10.1021/jm301470a
54. Cornall LM, Mathai ML, Hryciw DH, Mcainch AJ. GPR120 agonism as a countermeasure against metabolic diseases. Drug Discov Today (2014) 19:670-9. doi:10.1016/j.drudis.2013.11.021
55. Hudson BD, Shimpukade B, Mackenzie AE, Butcher AJ, Pediani JD, Christiansen E, et al. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol (2013) 84:710-25. doi:10.1124/mol.113.087783
56. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell (2010) 142:687-98. doi:10.1016/j.cell.2010.07.041
57. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature (2012) 483:350-4. doi:10.1038/nature10798
58. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med (2005) 11:90-4. doi:10.1038/nm1168
59. Paulsen SJ, Larsen LK, Hansen G, Chelur S, Larsen PJ, Vrang N. Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in Glp-1 secretion. PLoS One (2014) 9:e88227. doi:10.1371/journal.pone.0088227
60. Engelstoft MS, Park WM, Sakata I, Kristensen LV, Husted AS, Osborne-Lawrence S, et al. Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol Metab (2013) 2:376-92. doi:10.1016/j.molmet.2013.08.006
61. Gong Z, Yoshimura M, Aizawa S, Kurotani R, Zigman JM, Sakai T, et al. G protein-coupled receptor 120 signaling regulates ghrelin secretion in vivo and in vitro. Am J Physiol Endocrinol Metab (2014) 306:E28-35. doi:10.1152/ajpendo.00306.2013
62. Taneera J, Lang S, Sharma A, Fadista J, Zhou Y, Ahlqvist E, et al. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab (2012) 16:122-34. doi:10.1016/j.cmet.2012.06.006
63. Stone VM, Dhayal S, Brocklehurst KJ, Lenaghan C, Sorhede Winzell M, Hammar M, et al. GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans. Diabetologia (2014) 57:1182-91. doi:10.1007/s00125-014-3213-0
64. Suckow AT, Polidori D, Yan W, Chon S, Ma JY, Leonard J, et al. Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion. J Biol Chem (2014) 289:15751-63. doi:10.1074/jbc.M114.568683
65. Abdoul-Azize S, Selvakumar S, Sadou H, Besnard P, Khan NA. Ca2+ signaling in taste bud cells and spontaneous preference for fat: unresolved roles of CD36 and GPR120. Biochimie (2014) 96:8-13. doi:10.1016/j.biochi.2013.06.005
66. Halder S, Kumar S, Sharma R. The therapeutic potential of GPR120: a patent review. Expert Opin Ther Pat (2013) 23:1581-90. doi:10.1517/13543776.2013.842977
67. Li X, Yu Y, Funk CD. Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4). FASEB J (2013) 27:4987-97. doi:10.1096/fj.13-235333
68. Cintra DE, Ropelle ER, Moraes JC, Pauli JR, Morari J, Souza CT, et al. Unsaturated fatty acids revert diet-induced hypothalamic inflammation in obesity. PLoS One (2012) 7:e30571. doi:10.1371/journal.pone.0030571
69. Wellhauser L, Belsham DD. Activation of the omega-3 fatty acid receptor GPR120 mediates anti-inflammatory actions in immortalized hypothalamic neurons. J Neuroinflamm (2014) 11:60. doi:10.1186/1742-2094-11-60
70. Holliday ND, Watson SJ, Brown AJ. Drug discovery opportunities and challenges at g protein coupled receptors for long chain free Fatty acids. Front Endocrinol (Lausanne) (2011) 2:112. doi:10.3389/fendo.2011.00112
71. Shimpukade B, Hudson BD, Hovgaard CK, Milligan G, Ulven T. Discovery of a potent and selective GPR120 agonist. J Med Chem (2012) 55:4511-5. doi:10.1021/jm300215x
72. Hudson BD, Shimpukade B, Milligan G, Ulven T. The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). J Biol Chem (2014) 289:20345-58. doi:10.1074/jbc.M114.561449
73. Sparks SM, Chen G, Collins JL, Danger D, Dock ST, Jayawickreme C, et al. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett (2014) 24:3100-3. doi:10.1016/j.bmcl.2014.05.012
74. Cani PD, Everard A, Duparc T. Gut microbiota, enteroendocrine functions and metabolism. Curr Opin Pharmacol (2013) 13:935-40. doi:10.1016/j.coph.2013.09.008
75. Nohr MK, Pedersen MH, Gille A, Egerod KL, Engelstoft MS, Husted AS, et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology (2013) 154:3552-64. doi:10.1210/en.2013-1142
76. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes (2012) 61:364-71. doi:10.2337/db11-1019
77. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem (2003) 278:11312-9. doi:10.1074/jbc.M211609200
78. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem (2003) 278:25481-9. doi:10.1074/jbc.M301403200
79. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun (2003) 303:1047-52. doi:10.1016/S0006-291X(03)00488-1
80. Schmidt J, Smith NJ, Christiansen E, Tikhonova IG, Grundmann M, Hudson BD, et al. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem (2011) 286:10628-40. doi:10.1074/jbc.M110.210872
81. Hudson BD, Christiansen E, Tikhonova IG, Grundmann M, Kostenis E, Adams DR, et al. Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J (2012) 26:4951-65. doi:10.1096/fj.12-213314
82. Hudson BD, Tikhonova IG, Pandey SK, Ulven T, Milligan G. Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem (2012) 287:41195-209. doi:10.1074/jbc.M112.396259
83. Bindels LB, Dewulf EM, Delzenne NM. GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci (2013) 34:226-32. doi:10.1016/j.tips.2013.02.002
84. Bjursell M, Admyre T, Goransson M, Marley AE, Smith DM, Oscarsson J, et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab (2011) 300:E211-20. doi:10.1152/ajpendo.00229.2010
85. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun (2013) 4:1829. doi:10.1038/ncomms2852
86. Zaibi MS, Stocker CJ, O'Dowd J, Davies A, Bellahcene M, Cawthorne MA, et al. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett (2010) 584:2381-6. doi:10.1016/j.febslet.2010.04.027
87. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, GPR41. Proc Natl Acad Sci U S A (2008) 105:16767-72. doi:10.1073/pnas.0808567105
88. Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One (2012) 7:e35240. doi:10.1371/journal.pone.0035240
89. Ulven T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) (2012) 3:111. doi:10.3389/fendo.2012.00111
90. Wang Y, Jiao X, Kayser F, Liu J, Wang Z, Wanska M, et al. The first synthetic agonists of FFA2: discovery and Sar of phenylacetamides as allosteric modulators. Bioorg Med Chem Lett (2010) 20:493-8. doi:10.1016/j.bmcl.2009.11.112
91. Hudson BD, Due-Hansen ME, Christiansen E, Hansen AM, Mackenzie AE, Murdoch H, et al. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem (2013) 288:17296-312. doi:10.1074/jbc.M113.455337
92. Cornall LM, Mathai ML, Hryciw DH, Mcainch AJ. The therapeutic potential of GPR43: a novel role in modulating metabolic health. Cell Mol Life Sci (2013) 70:4759-70. doi:10.1007/s00018-013-1419-9
93. Hudson BD, Christiansen E, Murdoch H, Jenkins L, Hansen AH, Madsen O, et al. Complex pharmacology of novel allosteric free fatty acid 3 receptor ligands. Mol Pharmacol (2014) 86:200-10. doi:10.1124/mol.114.093294
94. Ito R, Tsujihata Y, Matsuda-Nagasumi K, Mori I, Negoro N, Takeuchi K. Tak-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and beta-cell dysfunction in Zucker diabetic fatty rats. Br J Pharmacol (2013) 170:568-80. doi:10.1111/bph.12297
95. Nakashima R, Yano T, Ogawa J, Tanaka N, Toda N, Yoshida M, et al. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. Eur J Pharmacol (2014) 737C:194-201. doi:10.1016/j.ejphar.2014.05.014